ProCE Banner Activity

CAPELLA: Wk 156 Results With LA SC Lenacapavir in Persons Living With Multidrug-Resistant HIV

Conference Coverage
Slideset

In the phase II/III CAPELLA trial in heavily treatment–experienced persons living with multidrug-resistant HIV infection receiving LA SC lenacapavir with optimized background regimen, continued virologic suppression and improvements in CD4+ cell count observed through Week 156.

Released: October 30, 2024

Expiration: October 29, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare